Can-Fite BioPharma

Can-Fite's business model revolves around the research and development (R&D) of synthetic, highly specific agonists and an allosteric modulator that target the A3 adenosine receptor (A3AR). This receptor is found in high levels in cancer and inflammatory cells but is minimally present in normal cells. By focusing on A3AR, Can-Fite aims to create treatments that are both effective and have fewer side effects.

The company's pipeline includes several orally bioavailable drugs in various stages of clinical trials. These drugs are designed to treat conditions such as liver cancer, psoriasis, rheumatoid arthritis, and other inflammatory diseases. Can-Fite generates revenue through licensing agreements, partnerships, and potential future sales of its proprietary drugs once they receive regulatory approval.

The company's technology platform is based on the discovery that the Gi protein-coupled A3 adenosine receptor is highly expressed in diseased cells but not in normal cells. This unique approach allows Can-Fite to develop targeted therapies that can potentially offer better efficacy and safety profiles compared to existing treatments.

Can-Fite is led by a team of experienced professionals, including CEO Dr. Pnina Fishman, a renowned scientist with extensive experience in clinical and tumor immunology, and Chairman Dr. Ilan Cohn, a senior partner at Israel's largest intellectual property firm.

In summary, Can-Fite BioPharma Ltd. is a pioneering biopharmaceutical company dedicated to developing targeted therapies for cancer and inflammatory diseases, leveraging its unique A3AR technology platform to create innovative treatments with the potential for high efficacy and low side effects.